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1. Introduction 
Cutaneous Melanoma is an aggressive cancer which accounts for 80% of skin cancer deaths. 
Australia has the highest incidence world-wide and rates are increasing annually (10,000 
new cases and 1,700 deaths per year). Notably it is the most common cancer in 15-39 year 
olds and the leading cancer related cause of death in young males (WA Cancer Registry 
2007). In the USA, incidence is rising faster than other cancers, with 60,000 new cases and 
8,000 deaths in 2007 1.  
Mortality rates remain high due to metastasis of the tumour. Once melanoma has 
metastasised, survival is commonly 6 to 9 months, with 5-year survival rate less than 40% 2-4. 
Several prognostic factors have been identified, based upon pathological evaluation of the 
primary tumour 5 and lymph node metastases 6. However, metastatic disease particularly 
micrometastasis, is difficult to detect and occurs in over 30% of patients, including 8-30% of 
patients with in situ melanoma 7-9 and 15% of patients whose lymph nodes are negative at 
the time of surgical intervention 10,11. In addition, metastasis can occur up to 35 years after 
diagnosis 12. Effective therapies providing long term survival are very limited (<20%), often 
due to drug resistance associated with prevailing undetected mutations or acquisition of 
new mutations. Surprisingly few studies 13-15 have monitored circulating cells as a means of 
determining disease progression, and/or treatment efficacy or for design of personalised 
treatment strategies. 
A great deal of information has been compiled in an attempt to identify prognostic factors 
that correlate with clinical outcomes. Current clinical staging is performed using measures 
of the pathological features of the primary tumour, lymph node and distant metastases 6, as 
well as LDH levels and now also, genetic changes in the primary tumour 16-19. The inability 
to accurately predict melanoma progression, may be related to the fact that the majority of 
studies use primary and less often, metastatic tumour tissue to stratify patients and 
delineate prognostic markers. Very few studies analyse the circulating tumour cell (CTC) 
phenotype that gives rise to the metastases. There is therefore an unmet need for detailed 
analyses of CTCs to provide early identification of metastatic risk and prognosis and 
evaluation of adjuvant therapies. 
2. Circulating tumour cells 
Millions of cells are shed from a tumour every day (approx 4 × 106 cells/g primary 
tumour) 20, and these cells invade lymphatic and/or venous circulatory systems. Once they 
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have entered the blood stream they become a circulating melanoma cell population. The fact 
that metastasis can occur many years after surgery indicates that disseminated tumour cells 
may remain in the blood stream for decades, evading the immune system and apparently 
remaining quiescent. Interestingly, few establish clinically diagnosed metastasis 21,22. Those 
that do, particularly after many years, must acquire some activating change 12.   
Since most cancer patients die as a result of metastatic spread rather than from their primary 
tumours 22,23, metastatic inefficiency of the primary tumour is likely overcome by the large 
number of tumour cells that enter the systemic circulation daily, estimated to be up to  
~4 × 106 tumour cells released per gram of primary tumour 20,24. Several studies have shown 
that the number of CTCs in patient peripheral blood increases with increasing stages of 
melanoma 25,26-29, 30. Yet the variety and phenotype of these CTCs, their ability to remain in 
circulation for many years thus evading the immune system, and their activation causing 
metastasis, remain largely unexplored, particularly for melanoma.  
3. Melanoma metastasis 
When cancer cells detach from the primary tumour and enter into blood vessels (or the 
lymphatic system), they can do so actively or passively 7. Passive cell intravasation, where 
cells are simply dislodged from the primary tumour, occurs as a result of increased 
hemodynamic flow 22,31,32. By contrast, active migration occurs in cells which have separated 
from their neighbours and actively migrate. In addition, many circulating cells are apoptotic 
or necrotic and are unlikely to survive immune cell destruction 33-37.  
The question remains then, is there a phenotypic and/or genotypic difference between cells 
that are able to survive in the circulation and metastasise from those that cannot? 
Fundamentally, gene expression signatures that prompt a melanoma cell to proliferate in 
situ must be different from those that permit a cell to actively migrate, and survive as a 
circulating cell, and then establish a secondary tumour. Several studies have documented 
the differential gene expression associated with malignant progression of melanoma. 
Pathways associated with initiation of melanoma metastasis include the transition from 
radial to vertical growth phase, epithelial to mesenchymal transitions, alterations in cell 
adhesion properties and suppression of apoptosis 38,39. Included are several key steps; loss of 
adhesion, dermal invasion, migration from the primary site, intravasation followed by 
survival in the blood, migration into target tissues, and increased proliferation in the new 
tissue microenvironment followed by orchestration of angiogenesis at the new site 40.  
Normal melanocyte cells in the epidermis are tethered tightly to other melanocyte cells and 
surrounding keratinocytes by cell surface molecules 41. Once they become proliferative and 
malignant, melanoma cells lose many of the cell surface proteins that secure the tight 
epithelial cell–cell adhesive interactions 33. One of the key cell surface proteins, CDH1 
(Cadherin 1, E-cadherin), is bound via its cytoplasmic tail to ┙-catenin and ┚-catenin, and 
thus to the actin cytoskeleton to maintain close cell junctions 42. Once melanoma cells 
become invasive, they no longer express CDH1, but express rather CDH5 (V-cadherin) or 
CDH2 (N-cadherin), proteins synonymous with the start of an epithelial to- mesenchymal 
transition (EMT) 43. The EMT process, commonly utilised by migrating cells during 
embryonic development, involves switching of polarised epithelial cells to contractile, 
motile mesenchymal progenitor cells, and is triggered by secretion of growth factors (EGF 
(epithelial growth factor), FGF (fibroblast growth factor)) and chemotactic/pro-migratory 
factors SF/HGF (hepatocyte growth factor) and chemokines from stromal fibroblasts and 
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macrophages. This secretion induces intracellular transduction pathways (Wnt, Notch) 
which in turn activate transcription factors (Twist and SNAI1 and 2) 44,45 bringing about the 
invasion of melanoma cells from the epidermal, dermal border to invasion of the dermis and 
entry of the cells into the circulation and metastasis 27,46. The invasive process is also the 
result of activated signalling cascades such as the NEDD9-DOCK3-Rac (Neural precursor 
cell expressed developmentally down-regulated protein 9- Dorsocross3 - Rac) pathway. The 
movement of these cells through the extracellular matrix and their migration towards blood 
vessels is assisted by integrin and matrix metalloproteinases 27,47-49. 
The next step in the active migration process is the attraction of tumour cells to lymph and 
blood vessels, a process mediated by ligand-receptor interactions between tumour cells and 
the stroma or endothelial cells. Tumour cells secrete CSF1 (colony stimulating factor 1) and 
growth factors such as EGF which activate the formation and proliferation of tumour-
associated macrophages in the stroma. These cells in turn secrete chemokines including 
SDF-1 (stromal-cell-derived factor 1), SCL/CCL21 (chemokine C-C motif ligand 21) and 
I309/CCL1 (chemokine C-C motif ligand 1), which assist with chemotaxis of tumour cells 
expressing the appropriate receptors, CXCR4, CCR7 and CCR8, into blood vessels 27,50,51.  
Whether cells actively move toward and into nearby blood vessels or whether the process is 
passive and coincidental may be of some significance. Expression of specific genes that 
assist entry into the circulation, either passively or actively, may determine cell survival and 
metastatic ability. That is cells expressing genes associated with EMT, or cell migration, may 
be more prone to tumourigenesis and metastasis.  
Model systems that quantify circulating cells leaving the tumour, show, in fact, that 3–4×106 
malignant cells/day are shed per gram of tumour suggesting that millions of cells may be 
shed from a tumour every day 24,52,53. Characterisation of these circulating tumour cells in 
patients with metastatic prostate and breast cancer indicates that they are predominantly 
apoptotic 37 or necrotic and unlikely to survive 34,35,36. Furthermore, circulating cells are often 
sheared and destroyed as they leave the tumour and enter the circulation. Moreover, 
immune cells in the circulation destroy the bulk of circulating cells and prevent all but the 
most active from producing metastases 33,54.  
Some cells do however survive for long periods of time in the vasculature 55,33 where they 
are usually found in clumps or clusters known as circulating tumour microemboli, 
surrounded by a “cloak” of platelets and leukocytes which assists tumour cell survival for 
some time by evasion of the immune system 56-58. Moreover, melanoma cell evasion of the 
immune system and thus survival in the blood stream is also due to the intracellular 
localisation of the ligand which typically activates NKD2D receptors on natural killer (NK) 
cells 59. Thus evasion from attack by natural killer (NK) cells affords melanoma cells a 
powerful means of protection from NK cell mediated cytotoxicity. Metastatic melanoma 
cells also develop resistance to inhibitory cytokines through the modification of oncostatin 
M receptors 60,61. With such an arsenal of survival mechanisms, melanoma cells may indeed 
survive in the circulation for long periods of time. 
4. Detection of CTCs 
Various methods have been used to quantify and characterise CTCs, including indirect 
methods, namely qRT-PCR 25,62-65, and direct analyses such as immunomagnetic bead 
capture, or fibre-optic array scanning technology 28,29,66,67,68. From these results it is obvious 
that; a) CTCs are present at relatively low concentrations; one tumour cell per 106 to 107 
www.intechopen.com
 
Breakthroughs in Melanoma Research 
 
46 
normal blood cells or on average, 1 cell per ml of blood 69,70,71; b) the number of cells appears 
to be related to stage 2,25,72; c) melanoma cell markers differ with respect to stage 73; and  
c) CTC gene expression differs from that of the primary tumour 28,29. 
Quantitative RT-PCR has typically detected expression of melanocytic genes such as 
tyrosinase (TYR) 74, 75 since normal melanocytes are not thought to circulate in peripheral 
blood and therefore detection of transcripts from melanocytic genes should correlate to 
identification of CTCs 72,76. The sensitivity and specificity of PCR for circulating melanoma 
cells is increased by analysis of multiple markers 76, and these commonly include melan-A 
(MLANA), beta-1,4-N-acetyl-galactosaminyl transferase 1 (B4GALNT1), silver homolog 
(SILV), melanoma cell adhesion molecule (MCAM), melanoma associated antigen p97 
(MFI2), melanoma antigen family A3 (MAGEA3) and microphthalmia-associated 
transcription factor 4 (MITF4) 63,64,77,78. Several studies have shown that levels of gene 
expression associated with melanoma CTCs in patient blood correlate to AJCC stage, 
survival and disease recurrence 2,25,72.  
Alternately, CTCs can be positively selected from whole blood using immunomagnetic 
beads 66. With this system, CTC numbers are shown to positively correlate with cell stage 
and be an independent prognostic indicator of progression-free and overall survival for 
breast cancer 79, melanoma 28 and many other cancers 71. 
5. Differential gene expression profiles of circulating  
The question remains then, how do we differentiate those cells that are able to survive in the 
circulation from those that cannot? Moreover, can we differentiate actively metastatic 
melanoma cells from those that are quiescent or apoptotic and is there a need to do so? It is 
thought that any cancer cell can acquire the ability to disseminate at any time, even early 
and prior to overt tumour formation 11,80. For heterogeneous tumours such as melanoma, an 
unstable, genetically-variant, invasive cell may metastasise at any time 27. Whether this  
is possible for all melanoma cells remains to be confirmed, but recent experiments suggest 
that all melanoma cells can initiate a new tumour when xenotransplanted into 
immunocompromised mice 81.  
By contrast a plethora of information gathered over many decades indicates that melanoma 
cells express stage related markers that are associated with a more or less invasive tumour 
73. In Fig 1, for example, we have shows differential stage related expression of the 
melanoma cell adhesion molecule, MCAM. At early disease stages, MCAM is found in <50% 
cells of 4/10 primary tumours, as opposed to metastatic tissue, where all cells are MCAM+ 
(5/5, 93% cells).82. MCSP, on the other hand, is found on >80% of melanoma cells at all 
stages I-IV 14,83-85 so its expression is not stage related. CTCs are also likely to have 
differential gene expression signatures related to stage and these may differ relative to those 
of the primary tumour as previously demonstrated 28,29. It is apparent that merely 
identifying the presence of CTCs using for example MCSP, does not necessarily provide 
evidence of disease progression. It may be necessary to analyse CTC phenotype or genotype 
to obtain more prognostic information. 
In recent years a number of researchers have shown the existence of a sub-set of tumour 
initiating or melanoma stem cells within the primary tumour 86-90. These cells are believed to 
be responsible for relapse and metastasis by virtue of their ability to survive treatment and 
initiate new tumour formation. Rare cancer stem cells would therefore be capable of 
effectively managing the metastatic process 91 and would act as stem cells for metastasis 
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formation at a new site 69. Melanoma stem cell markers include JARID1B (jumonji, AT rich 
interactive domain 1B) 92, ABCB5 (ATP-Binding Cassette Subfamily B (MDR/TAP) Member 
5), ABCG2 (ATP-binding cassette sub-family G member 2), MDR1 (Multi-Drug Resistance 1) 
87,93-99 and more recently CD271 100.  
6. Markers of metastasis – Can they be identified in CTCs?  
A plethora of studies have focused on identification of markers with sufficient specificity to 
accurately predict melanoma progression. Although many of these were identified using 
primary tissue or melanoma cell lines, they have been used for the multitude of CTC studies 
conducted thus far 72,101-103. For qRT-PCR analysis of CTCs include SILV, MLANA, TYR, 
MAGEA3 and MAGE-A10 25,62-64,72,104, or more recently, ABCB5 86,87 105. From high throughput 
analyses of melanoma gene expression, several key progression pathways have been 
identified 38,39,103,106,107 but remain to be tested as informative for CTC analysis. Key amongst 
these pathways are: tyrosine kinase receptors (TKRs) (e.g. VEGFR, ERBB2, TGF-betaR), the 
Ras / Raf / MEK / ERK pathway, the PI3K / Akt / PTEN / mTOR pathway, cell cycle 
regulation pathways (Rb / p53 / p16INKA / p14ARF / HDM2), epigenetic gene expression 
regulation and DNA repair pathways (DNA methylation, histone acetylation, RNA 
interference), apoptotic pathways (e.g. death receptors: FAS, TRAILR, TNFR; mitochondrial 
pathway: Bcl2 family), common apoptosis effectors, protein chaperoning, degradation (HSP, 
proteasome) 25,108,109 and epithelial to mesenchymal transition (reviewed in 110). A thorough 
screening of CTCs from metastatic melanoma patients for these activated pathways needs to 
be performed so as to establish their involvement in CTC survival, proliferation and intra- 
and extravasation. By detecting the presence and/or levels of genes associated with these 
activated / metastatic pathways, CTC analyses might be significantly enhanced.  
Several reports also suggest that, in melanoma cells, altered regulation of melanocyte 
developmental pathways, are key to the acquisition of metastatic potential 111-116. Indeed, 
melanoma metastasis reflects to some extent the migratory capacity of melanoblast 
developmental precursors, the neural crest cells. Moreover, genes that are critical for 
melanocyte development have been recognised as important factors of melanoma growth, 
for example MITF, DCT and SOX10 all function to maintain the stem or progenitor cell 
population of melanoblasts during migration from the neural crest and during melanoblast 
survival in the hair follicle niche 72,110,117-119 and may be equally important in melanoma cell 
maintenance and migration. It is important then to identify the expression of these 
developmental genes in CTCs and assess their association with metastasis. 
7. Mutations in circulating melanoma cells 
There is increasing evidence that melanoma metastasis is activated by mutations in multiple 
pathways including MAPK-ERK, PI3/AKT, PTEN and retinoblastoma pathways that 
regulate cyclin-dependent kinases (CDKs) (Table 1) 120,121. MITF, a key transcription factor, is 
amplified in melanoma, and also regulated by c-KIT via MAPK/ERK and PI3/AKT 
pathways 122. Differing mutations in multiple pathways have also now been identified for 
different melanoma subtypes 120,123,124. It remains for stage and subtype related mutations to 
be profiled in CTCs.  
There are currently eight defined subtypes of melanoma, based on mutations in key 
melanoma genes, but not all melanoma cases fit into these subtypes 125. The majority of 
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melanomas will have a mutation in either BRAF (57%) or NRAS (17%) but rarely have both 
124. Further details about known mutations are described below. 
 
 Pathway(s) activated by mutations 
1. MAPK 
2. c-KIT 
3. GNAQ/GNA11 
4. NRAS 
5. MITF 
6. AKT/PI3K 
7. CDK 
8. P53/BCL 
9. Undetermined 
Table 1. Melanoma subtypes – adapted from Vidwans et al. 125 
Many new treatments being developed for melanoma target these specific molecular 
pathways which are associated with tumour progression. Unfortunately the effectiveness of 
these potential treatments has so far been limited by drug resistance as a result of newly 
acquired mutations 126 or the inadequate analysis of existing additional mutations. Since the 
presence or absence of certain mutations can drastically effect the success of targeted 
treatments it would be of benefit to develop a detailed profile of mutations that exist in an 
individual patient to maximise efficacy of treatment. One possibility is to use CTCs for stage 
and subtype related mutation analysis. 
8. Conclusion 
From our own (Fig. 1) and many other reported studies 33-36,54, it is clear that positivity per se 
is not necessarily a prognostic indicator i.e. it is possible that not all circulating cells 
establish successful tissue metastases. Thus a more comprehensive set of experiments and 
additional markers are required to better understand the diagnostic and prognostic 
significance of circulating melanoma cells. These issues are best addressed by isolation, 
characterisation and quantification of circulating melanoma cells. Additionally, newly 
identified prognostic markers need to be measured in CTCs and assessed relative to patient 
outcome to delineate the metastatic potential of circulating melanoma cells and their 
usefulness as a prognostic indicator 72,127. 
We hypothesise that the ability of circulating melanoma cells to become activated, 
proliferative and migratory from a quiescent cell depends on several key genes. An alternate 
hypothesis is that malignant cells disseminate from the primary tumour early in 
tumourigenesis and remain in a clinically latent state until either the cells themselves or the 
host environment is receptive to the development of metastases. Quintana and colleagues 81 
and more recently Roesch et al., 92 show that single human melanoma cells with no 
specifically identifiable gene signature can re-establish melanoma tumours when 
xenotransplanted into severely immunocompromised mice. It is of paramount importance 
therefore that we identify pathways associated with metastasis of circulating cells, ie those 
pathways that confer metastatic properties on quiescent melanoma stem cells capable of 
evading human anti-tumour immune responses. Furthermore, it is necessary to identify 
whether CTC numbers, gene expression profiles, or a combination of both, are key factors in 
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patient outcome. It also remains to be seen whether tumour related DNA mutations and the 
resultant activated proteins provide more accurate measures of melanoma progression. A 
combination of marker types is likely to be more accurate than measures that determine the 
presence and quantity of CTCs alone. Future studies in this field will need to be performed 
to address the multitude of issues alluded to in this chapter. 
 
 
Fig. 1. A) Double immunofluorescent staining showing PAX3 (mouse monoclonal antibody, 
DSHB) and MCAM co-expression in normal skin (epidermal melanocytes), naevus, primary 
melanoma and melanoma metastasis respectively. Lines in (A) demarcate the epidermal-
dermal border (EDB) or epidermal surface (ES). B) Graph showing the overall number of 
PAX3, MCAM double-labelled cells in normal skin, naevi, primary melanomas and melanoma 
metastases. Each column represents a percentage of PAX3-positive, MCAM-positive, averaged 
across all samples. Note: MCAM positive cells were all PAX3 positive (revised from 73) 
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